To more than $ 1 billion estimated annually. There currently is no effective treatment for rotavirus. – ‘These findings could have global consequences,’said Jean-Francois Rossignol, Chairman and Chief Science Officer of the Romark Institute for Medical Research.. In a research paper published today in The Lancet, an internationally recognized medical journal, reported the researchers, that can 3 – 3 – day course of nitazoxanide significantly the duration of severe dehydrating rotavirus diarrhea and gastroenteritis in children. The results of the research, at Cairo University, the Children’s Hospital were conducted in Egypt, published online, the 7th International Rotavirus Workshop in Lisbon, Portugal, June 12 to 13 2006 in The Lancet. Nitazoxanide more than 1 40 children 40 children aged under five admitted due to rotavirus diarrhea in the hospital.
– World Congress on Industrial Biotechnology & Bioprocessing April 27-30, 2008 Chicago, – 2008 BIO International Convention June 17 – 20, 2008 in San Diego,in Egypt the treatment of rotavirus had worldwide impact on the health of the childrenRomark Laboratories announced today that findings from research into the use of its drug, nitazoxanide, for the treatment of rotavirus could substantially reduce the impact of these viral illness mostly children. Rotavirus is the leading cause of morbidity and mortality in children younger than 5 years old, which estimated 500,000 deaths each year worldwide.. Upcoming BIO Events – BIO-Asia Partnering Conference January 28 to 29, 2008 Tokyo, Japan – BIO CEO & Investor Conference February 11 to 13, 2008 New York, NY – Partnering for Global Health 10 to 12 March 2008 Washington, DC – BIO-Europe Spring April 7-9, 2008 Madrid, Spain – BIO National venture Conference April 22-23, 2008 Boston, Mass.High tech equipment revolutionizing the way surgery is done, so that the surgeon with greater accuracy and hardly any physical exertion carry – I believe may KIS do to anesthesia what these systems done to surgery say Dr. Armen Aprikian, MUHC Director the urology department the surgery at the first patients treatment done by which HIS. Hemmerling, which lab develop the worldwide first Anaesthesia robot which. The nickname of McSleepyTM, in the year 2008 which anesthetic anesthesia.
The single-arm is replaced Special Protocol Assessment process To SGN-35 pivotal trial in Hodgkin lymphoma.
The single-arm pivotal trial will be the efficacy and safety of monotherapy SGN-35 in the 100 patients with recurrent and refractory Hodgkin lymphoma, to evaluate the previously received autologous SCT. Patient receive 1.8 milligrams per kg of SGN-35 every three weeks. Its primary endpoint study will objective response rate are radiologic radiology system. Secondary endpoints include durability of the response, highly compatible overall survival and tolerability.